Evidence guide · US
Psyllium husk alongside GLP-1 medicines: what the trials show on constipation, weight and safety
Constipation was reported by 24% of adults on Wegovy 2.4 mg in label trials. What trials show for psyllium on constipation, weight and blood glucose, and how to take it safely, with rules for the UK, US, UAE and South Africa.
Review type: research summary. This page summarises published research and product labels, cited below.
Constipation is one of the most common side effects on the Wegovy label. Semaglutide is also sold as Ozempic, and tirzepatide as Mounjaro and Zepbound; those products have their own labels. Psyllium husk is a gel-forming fiber, sold in the UK as ispaghula husk (Fybogel is the example the NHS names). A July 2026 review in the International Journal of Molecular Sciences argues that a psyllium-centered fiber strategy may help close the "fiber gap" during these treatments. The review is a narrative one. Its authors call the pain and mood implications hypothesis-generating, because direct clinical evidence that psyllium or glucomannan improves those outcomes remains limited.
Short answer: psyllium has the best trial record of any fiber for constipation in people with chronic constipation, at doses above 10 g a day taken for at least four weeks. No published randomized trial has studied psyllium on its own for constipation in people taking GLP-1 medicines, so that is an extrapolation. For weight, the trials disagree and the pooled results do not support taking psyllium to lose more weight. Psyllium must be taken with plenty of fluid.
Grades used here: Strong (consistent results from several good-quality human trials), Moderate (good trials, but few or with mixed results), Limited (small or low-quality human studies, or good studies in other groups of people), Insufficient (too little human research to judge) and Evidence of harm.
How common is constipation on a GLP-1 medicine?
The current US prescribing information for Wegovy lists constipation in 24% of adults taking the 2.4 mg weekly injection for weight reduction (2,116 people), against 11% on placebo (1,261 people). In a separate trial table for the 7.2 mg dose, constipation was reported by 20% on 7.2 mg (1,311 people), 19% on 2.4 mg (304 people) and 8% on placebo (303 people). The label also lists ileus, intestinal obstruction and severe constipation including fecal impaction among reports received after approval. Other GLP-1 medicines have their own labels. On this Wegovy label the constipation rate already differs by dose and by trial.
Psyllium for constipation: Moderate (in people with chronic constipation)
A 2022 systematic review from King's College London pooled 16 randomized trials with 1,251 adults with chronic constipation. Overall, 66% of people given fiber responded, against 41% given control treatment (risk ratio 1.48, 95% CI 1.17 to 1.88), and psyllium and pectin were the fibers with significant effects. Benefits were clearest with doses above 10 g a day, and stool frequency improved only with higher doses and treatment of at least four weeks. Flatulence was higher in the fiber groups, and the authors warn that the results varied considerably between trials.
A 2021 US trial compared 12 g a day of psyllium, two green kiwifruit or 100 g of prunes for four weeks in 79 adults with chronic constipation (75 with complete data, 22 of them on psyllium). Weekly complete spontaneous bowel movements rose significantly with all three, and straining improved with psyllium. Side effects were most common with psyllium and least common with kiwifruit. The trial was small and only partly randomized, so it is a pointer, not proof.
Both sets of trials enrolled people with chronic constipation in general. Neither paper studied people taking GLP-1 medicines. A Delphi consensus statement on nutrition and GLP-1 medicines, published in November 2025 in Obesity Pillars (volume 17, issued for 2026), covers constipation among its 52 statements. It says those statements were derived primarily from indirect evidence and that further direct evidence is urgently required.
Psyllium for weight: Moderate (mixed results, and not in people taking GLP-1 medicines)
A 2020 dose-response meta-analysis of 22 randomized trials found no significant effect of psyllium on body weight (mean difference -0.28 kg, 95% CI -0.78 to 0.21), BMI or waist circumference. A 2023 meta-analysis of six trials in 354 people with overweight or obesity, taking psyllium just before meals for an average of 4.8 months, reported a 2.1 kg greater weight loss (95% CI 1.6 to 2.6 kg). Its authors are employees of Procter & Gamble, which makes the psyllium product Metamucil. A 2025 meta-analysis of 27 trials reported a body-weight increase (weighted mean difference 3.57 kg, 95% CI 1.43 to 5.72) and no significant change in BMI. The authors call that increase unexpected and its clinical meaning uncertain, and they say it may reflect water held in the gut. Variation between trials was very high, and leaving one study out at a time produced estimates from 0.18 kg to 5.35 kg. The study table also includes flaxseed mucilage and Plantago major, not only psyllium.
These pooled analyses do not agree, so psyllium cannot be called a weight-loss aid. None of them were in people taking GLP-1 medicines. The 2026 review's idea that viscous fiber may support the gut hormone pathway is a hypothesis, and its authors describe the pain and mood implications as hypothesis-generating.
Psyllium and blood glucose: Moderate (in the studies pooled)
A 2024 GRADE-assessed meta-analysis of 19 randomized trials found that, compared with placebo, psyllium lowered fasting blood sugar, HbA1c (weighted mean difference -0.75, 95% CI -1.21 to -0.29) and HOMA-IR, but not insulin. Fasting blood sugar was available for 962 adults and HbA1c for 523. The HbA1c effect was not significant at doses below 10 g a day. Because GLP-1 medicines also change glucose, anyone taking them for type 2 diabetes should ask their prescriber before adding a fiber supplement that may add to the effect.
Safety: fluid, swallowing and other medicines
Psyllium swells into a gel. The NHS advises drinking plenty of fluids when taking bulk-forming laxatives such as Fybogel (ispaghula husk), which it describes as increasing the fiber in poo to make it bigger and softer. In the US, 21 CFR 201.319 requires OTC drug products that contain psyllium, glucomannan or similar gums as an active ingredient, when sold dry or incompletely hydrated, to carry a choking warning, to direct each dose to be taken with at least 8 ounces (a full glass) of water or other fluid, and not to be used by people who have difficulty swallowing.
The Wegovy label says delayed gastric emptying has the potential to affect the absorption of oral medicines taken with it, and advises monitoring their effects. A fiber supplement is an extra thing in the gut at the same time, so a pharmacist or prescriber is the right person to ask whether it should be separated from other tablets. Flatulence was higher with fiber in the constipation trials, and severe or persistent constipation, vomiting or abdominal pain on a GLP-1 medicine needs medical advice, not more fiber.
Our view
- Psyllium is a reasonable first fiber to ask a pharmacist about for constipation, with at least a full glass of fluid, because it has the strongest trial record. That record comes from people with chronic constipation, not from GLP-1 users.
- Food fiber from vegetables, fruit, cereals and oats comes first. The NHS advises a healthy balanced diet, plenty of water and other fluids, and gradually increasing the fiber in the diet as self-help steps for constipation.
- Do not take psyllium as a weight-loss add-on. The pooled results conflict, and those trials were not in people taking GLP-1 medicines.
- Keep fluids up. Seek advice before starting if you have trouble swallowing or take diabetes medicines. The NHS also says to check with a pharmacist or doctor before a laxative if you have a digestive condition such as Crohn's disease or ulcerative colitis.
US rules
Under 21 CFR 201.319, OTC drug products that contain psyllium (plantago seed), glucomannan or similar gums as an active ingredient must carry a choking warning and directions to take each dose with at least 8 ounces (a full glass) of water or other fluid when sold dry or incompletely hydrated. Report suspected side effects of a medicine to the FDA through MedWatch.
FAQ
Does psyllium help constipation on Wegovy or Mounjaro?
Psyllium helps constipation in trials of people with chronic constipation, at doses above 10 g a day for at least four weeks. No published randomized trial has studied psyllium on its own for constipation in people taking GLP-1 medicines.
Will psyllium help me lose more weight on a GLP-1 medicine?
There is no evidence that it does. Pooled trials gave conflicting results: no effect in 22 trials, a 2.1 kg loss in six trials analyzed by employees of a psyllium manufacturer, and a 27-trial analysis that reported a weight increase the authors call unexpected and uncertain. None of these analyses studied psyllium on its own in people taking GLP-1 medicines.
How much water do I need with psyllium?
US federal labeling rules for OTC drug products that contain psyllium as an active ingredient, when sold dry or incompletely hydrated, require directions to take each dose with at least 8 ounces (a full glass) of water or other fluid. Follow the directions on your own product.
Is psyllium the same as glucomannan?
No. Both are viscous, gel-forming fibers and both are covered by the same US choking-warning rule, but psyllium has the stronger evidence for constipation. The 2026 review says glucomannan may support fullness when it is appropriately hydrated and tolerated.
Sources
These are the documents this page relies on.
- WEGOVY (semaglutide) prescribing information, Novo Nordisk (DailyMed label version of June 18, 2026): Tables 3 and 4, sections 6.2 and 7.2DailyMed, US National Library of Medicine
- van der Schoot A, Drysdale C, Whelan K, Dimidi E. The effect of fiber supplementation on chronic constipation in adults: an updated systematic review and meta-analysis of randomized controlled trials. Am J Clin Nutr. 2022;116(4):953-969American Journal of Clinical Nutrition (PubMed 35816465)
- Chey SW, Chey WD, Jackson K, Eswaran S. Exploratory comparative effectiveness trial of green kiwifruit, psyllium, or prunes in US patients with chronic constipation. Am J Gastroenterol. 2021;116(6):1304-1312American Journal of Gastroenterology (PubMed 34074830)
- Yoon Y, Hwang J, Yang CM, et al. Psyllium and glucomannan as viscous fiber modulators of the gut-microbiome-incretin axis: molecular links to metabolic inflammation, barrier function, and GLP-1 receptor agonist therapy. Int J Mol Sci. 2026;27(14):6287International Journal of Molecular Sciences (PubMed 42511630)
- Darooghegi Mofrad M, Mozaffari H, Mousavi SM, Sheikhi A, Milajerdi A. The effects of psyllium supplementation on body weight, body mass index and waist circumference in adults: a systematic review and dose-response meta-analysis of randomized controlled trials. Crit Rev Food Sci Nutr. 2020;60(5):859-872Critical Reviews in Food Science and Nutrition (PubMed 30880409)
- Gibb RD, Sloan KJ, McRorie JW Jr. Psyllium is a natural nonfermented gel-forming fiber that is effective for weight loss: a comprehensive review and meta-analysis. J Am Assoc Nurse Pract. 2023;35(8):468-476Journal of the American Association of Nurse Practitioners (PubMed 37163454)
- Gholami Z, Paknahad Z. The effect of psyllium consumption on anthropometric indices: a systematic review and dose-response meta-analysis of randomized controlled trials. J Health Popul Nutr. 2025;44(1):372Journal of Health, Population and Nutrition (PubMed 41126340)
- Gholami Z, Clark CCT, Paknahad Z. The effect of psyllium on fasting blood sugar, HbA1c, HOMA IR, and insulin control: a GRADE-assessed systematic review and meta-analysis of randomized controlled trials. BMC Endocr Disord. 2024;24(1):82BMC Endocrine Disorders (PubMed 38844885)
- Sievenpiper JL, Ard J, Blüher M, et al. Nutritional and lifestyle supportive care recommendations for management of obesity with GLP-1-based therapies: an expert consensus statement using a modified Delphi approach. Obes Pillars. 2025;17:100228 (2026 volume issue)Obesity Pillars (PubMed 41502845)
- Laxatives: types of laxative and how they workNHS
- Constipation: how you can treat and prevent constipation yourselfNHS
- 21 CFR 201.319: water-soluble gums, hydrophilic gums, and hydrophilic mucilloids (including plantago seed (psyllium) and glucomannan) as active ingredients; required warnings and directionsUS Code of Federal Regulations (eCFR)
- MedWatch: the FDA safety information and adverse event reporting programUS Food and Drug Administration